New Clinical Trials for Kidney Cancer

Two new clinical trials for kidney cancer are available at Lehigh Valley Health Network through its partnership with Memorial Sloan Kettering Cancer Center, giving patients options for experimental treatment and participation in research that advances kidney cancer treatment.

The immunotherapy trials test combinations of drugs that cut off blood supply to tumor cells and help the immune system find and fight cancer cells.

A decade ago, late-stage kidney cancer patients had a small chance of living past a year after diagnosis, said Dr. Suresh Nair, medical director of LVHN Cancer Institute.

“The amount of progress that’s happened in the year is staggering,” he said. “Kidney cancer has probably progressed the most among all the cancer areas in the past year.”

On Thursday, about 30 patients made it to their second annual celebration of advancements in kidney cancer treatment. The event, which was sponsored by the Andy Derr Foundation for Kidney Cancer Research and hosted by LVHN and Memorial Sloan Kettering at Lehigh Country Club, also featured a talk by leading kidney cancer doctor and researcher Dr. Robert Motzer, an oncologist at Memorial Sloan Kettering.

Kidney cancer research had a major breakthrough in 2006, when a Pfizer drug sunitinib won approval from the Food and Drug Administration, Motzer said. The drug cut off blood flow to tumors and prolonged life for late-stage kidney cancer patients.

Since then, survival rates continue to climb due to new generations of sunitinib, including one used by LVHN doctors called cabozantinib, and advancements in immunotherapy, which boosts the immune system to fight cancer.

But there’s a lot more progress to be made.

“That’s why efforts like your own are so important,” Motzer said at LVHN’s event. “That’s what gets the work done.”

Every year, more than 37,000 men and 21,000 women get kidney and renal pelvis cancers, according to the U.S. Centers for Disease Control and Prevention, and more than 13,000 die.

LVHN offers six clinical trials for kidney cancers, including the two newest.

New treatments give patients such as Lackawanna County resident Arlene Townsend a second chance at life. She’s participating in an LVHN immunotherapy trial launched last year.

Before her diagnosis, Townsend, 38, was easily irritated and didn’t have any passion for her job or life.

“It use to be get up, go to work, come home, make dinner,” she said. “It was kind of just going through the motions.”

She had to develop a positive attitude to cope with the physical and emotional toll of her late-stage kidney cancer, which had spread to her bones, lung and the lymph nodes around the heart in 2016, she said. Since her diagnosis, she found a passion for refurbishing furniture, let go of her cynicism and found happiness in life’s small moments.

“If I’m driving — it sounds silly — I notice the clouds,” she said.

“You don’t realize how many great things you have in your life until you think you’re not going to have them anymore.”

The change was so apparent that her husband noticed.

“He thinks I’m much happier,” she said.


CLINICAL TRIALS

Lehigh Valley Health Network and Memorial Sloan Kettering have partnered to bring new cancer treatments to the Lehigh Valley.

What is a clinical trial: A study involving patients who volunteer to receive new medications or treatments under evaluation.

Who may participate: Criteria are unique to each trial but often are based on age, gender, health and medical history. They are designed for participants most like those who will eventually receive the new drugs.

Source: Lehigh Valley Health Network

More information: At lvhn.org, search “clinical trials.”

From http://www.mcall.com/business/healthcare/mc-nws-biz-clinical-trials-kidney-cancer-20180406-story.html

Chronic Migraine Study

 

 

Chronic migraine headaches can interfere with work, family, and leisure.

Medications may not manage the pain, nausea, dizziness and other symptoms associated with migraines. This trial may help people suffering from chronic migraines maintain their lifestyle better – and it pays!

Learn more about this trial.

Clinical Trial for Cluster Headaches

cluster-headache

Cluster Headache is one of the most painful types of headaches. It’s frequently described as pain that occurs around, behind, or above the eye and along the temple in cyclic patterns or “clusters.” There are more than 200,000 cases of Cluster Headaches in the U.S. per year, and many patients describe it as a “drilling” type of sensation.

Right now, a local clinical research study is testing an investigational medication to see if it may help people who suffer from cluster headache (Investigational means the medication isn’t approved for routine clinical use).

If you qualify for this research study, you may have the opportunity to try this investigational medication. You may also receive study-related care at no cost, and compensation may be provided.

Learn more about this study here: http://curec.lk/1Uaj36v

Exelixis’ Kidney Cancer Drug Cabometyx Positive in Phase II

Exelixis, Inc. (EXELAnalyst Report) announced positive top-line data from the phase II trial, CABOSUN, on Cabometyx in patients suffering from previously untreated advanced renal cell carcinoma (RCC).

Results showed that Cabometyx led to significant improvement in progression-free survival in patients with previously untreated advanced RCC, compared with sunitinib. Consequently, the trial met its primary endpoint.

Safety data from the Cabometyx arm of the study were consistent with those observed in previous studies in patients with advanced RCC.

Final results of the trial will be presented at a medical conference shortly.

We remind investors that Cabometyx (the tablet formulation of cabozantinib) was approved by the FDA in Apr 2016 for the treatment of patients with advanced RCC, who have received prior anti-angiogenic therapy.

Meanwhile, the European Medicines Agency (EMA) has accepted a Marketing Authorisation Application (MAA) for Cabometyx for review in the same indication. Upon a potential approval, the drug would be marketed in the EU by Exelixis’ partner, Ipsen. The MAA has been granted accelerated assessment by the EMA’s Committee for Medicinal Products for Human Use (CHMP), which translates a review period of 150 days instead of the standard 210 days.

Exelixis also plans to submit results of the CABOSUN trial to regulatory authorities in order to discuss further development of Cabometyx and submission strategy for the treatment of first-line advanced RCC.

As per the American Cancer Society, kidney cancer is one of the top 10 most commonly diagnosed forms of cancer in both men and women in the U.S. Hence, approval of Cabometyx in first-line advanced RCC will boost its growth prospects significantly.

Exelixis currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare sector include Abbott Laboratories (ABT – Analyst Report) , Johnson & Johnson (JNJ – Analyst Report) and Sanofi (SNY – Analyst Report) . All three stocks carry a Zacks Rank #2 (Buy).

From https://www.zacks.com/stock/news/218403/exelixis-kidney-cancer-drug-cabometyx-positive-in-phase-ii

Bee’s Knees, Continued

bees-knees

 

My left knee is still bothering me, even after doing Physical Therapy since January. <sigh>
It seems to get better, then something happens and it’s back to pain again.  When we were on a trip to New York a month ago, we walked a lot and climbed so many stairs, I had to buy a new brace.
Today is supposed to be my final PT but I don’t think I’m ready.
When this clinical trial came to my email, I just went through the whole survey for this but there was no doctor nearby:
 
Osteoarthritis Research Studies. Knee and hip arthritis studies enrolling now. No-cost medication. http://curec.lk/1VL5hu9
 
We’ll see what the next step is (so to speak!)
Someday…
no-pain

New Study for People with Mild to Moderate Alzheimer’s Disease

alzheimer-white

The purpose of this study is to investigate whether the study medication can help people with mild to moderate Alzheimer’s Disease improve their mental abilities such as understanding, reasoning, and judgment. The study medication will be given together with an FDA-approved Alzheimer’s medication: Aricept® (donepezil), Exelon® (rivastigmine) or Razadyne® (galantamine).

More about the study:

  • The study drug (MK-7622) is administered in the form of one capsule a day in the morning.
  • There will be 830 participants in this trial

If you are interested, please find the full study details and eligibility criteria listed here.

Eligibility Criteria:

Participants must:

  • be between 55 – 85 years old
  • be diagnosed with mild to moderate Alzheimer’s Disease (12 – 24 MMSE)
  • have a trial partner who is able to attend any study visits that require assessment
  • be currently taking a stable daily dose of acetylcholinesterase inhibitor (AChEI) such as Aricept® (donepezil), Exelon® (rivastigmine patch oral), or Razadyne® (galantamine)

Participants must not:

  • have a history of seizures or epilepsy within the last 5 years
  • have a history of mental illness
  • have been diagnosed or treated for cancer within the past 5 years (excluding basal cell, squamous cell skin cancer, in situ cervical cancer and localized prostate cancer)

Please complete the online questionnaire to check if you’re eligible for the trial.

If you’re not familiar with clinical trials, here are some FAQs:

What are clinical trials?

Clinical trials are research studies to determine whether investigational drugs or treatments are safe and effective for humans. All new investigational medications and devices must undergo several clinical trials, often involving thousands of people.

Why participate in a clinical trial?

You will have access to new investigational treatments that would be available to the general public only upon approval. You will also receive study-related medical care and attention from clinical trial staff at research facilities. Clinical trials offer hope for many people and an opportunity to help researchers find better treatments for others in the future.

Learn why I’m talking about this Clinical Trial

FREE Patient and Survivor Conference in Northern California!

Other Stuff, Part 2: Kidney Cancer

 

 

From the Kidney Cancer Association:

 

REGISTER FOR FREE NOW!

2015 Kidney Cancer Association
Patient & Survivor Conference – Northern California

Saturday, August 15, 2015
8:00am – 3:00pm

Stanford Cancer Center

875 Blake Wilbur Drive, Palo Alto, CA 94304

Agenda has been posted. Click here to register for FREE today!

Learn about the latest treatments for kidney cancer, clinical trials and nutrition.

This conference is open to all patients, survivors, caregivers and family members. There is no cost to attend.

 Click here to register!

Click here for a list of nearby hotels. 

Please contact help@kidneycancer.org with questions or for more information.